It is indicated for the treatment of adult patients with the following conditions: Metastatic colorectal cancer who have received prior treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if they have RAS wild-type, an anti-EGFR therapy
10.1042/bsr20201807 38 GuoC.DengG.HanY.ChenY.CaiC.ShenH.et al (2021)
Elevated plasma TMAO levels have been associated in several studies with a higher risk of cardiovascular events and death [11, 67]
The carefully designed dose escalation schedulefrom 0.25 mg to 2.4 mg weekly over 1620 weeksis based on extensive clinical trials to minimise gastrointestinal side effects whilst optimising therapeutic benefit
2021;49:123131.JAMA Network
2), it is clear that targeting the right audience is fundamental in improving diagnosis and treatment of SPIGFD